These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11975786)

  • 1. Disease management and pharmacoeconomics as tools for mass prevention of hypertensive complications.
    Goldberg Arnold RJ
    Heart Dis; 2001; 3(3):152-6. PubMed ID: 11975786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic factors in the initiation of antihypertensive therapy.
    Kawachi I
    Pharmacoeconomics; 1992 Oct; 2(4):324-34. PubMed ID: 10147045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease management, pharmacoeconomics, and molecular biology: tools for prevention of hypertensive complications.
    Materson BJ
    Am J Hypertens; 1998 Aug; 11(8 Pt 2):101S-102S; discussion 109S-111S. PubMed ID: 9717850
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cardiovascular risk management in the hypertensive patient].
    Pereira S
    Acta Med Port; 2010; 23(2):223-6. PubMed ID: 20470469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic considerations in the management of hypertension.
    Pardell H; Tresserras R; Armario P; Hernández del Rey R
    Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
    Jackson R
    J Hum Hypertens; 1998 Sep; 12(9):607-13. PubMed ID: 9783489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
    Simons WR
    Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
    Milne RJ; Vander Hoorn S; Jackson RT
    Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Socioeconomic Effects of Uncontrolled Hypertension.
    Athanasakis K
    Curr Vasc Pharmacol; 2017; 16(1):5-9. PubMed ID: 28412912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.
    Whittington R; Faulds D
    Pharmacoeconomics; 1994 Jun; 5(6):513-54. PubMed ID: 10147266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic challenges in disease management of hypertension.
    Ambrosioni E
    J Hypertens Suppl; 2001 Sep; 19(3):S33-40. PubMed ID: 11713849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective.
    Fletcher AE; Bulpitt CJ
    Pharmacoeconomics; 1992 Jan; 1(1):33-44. PubMed ID: 10147038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Zanchetti A
    J Hypertens; 2006 Aug; 24(8):1671-7. PubMed ID: 16877972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities to improve the cost-effectiveness of treatment for hypertension.
    Stason WB
    Hypertension; 1991 Sep; 18(3 Suppl):I161-6. PubMed ID: 1909687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.